261 related articles for article (PubMed ID: 19946719)
1. Antimalarial evaluation of copper(II) nanohybrid solids: inhibition of plasmepsin II, a hemoglobin-degrading malarial aspartic protease from Plasmodium falciparum.
Mohapatra SC; Tiwari HK; Singla M; Rathi B; Sharma A; Mahiya K; Kumar M; Sinha S; Chauhan SS
J Biol Inorg Chem; 2010 Mar; 15(3):373-85. PubMed ID: 19946719
[TBL] [Abstract][Full Text] [Related]
2. Picomolar Inhibition of Plasmepsin V, an Essential Malaria Protease, Achieved Exploiting the Prime Region.
Gambini L; Rizzi L; Pedretti A; Taglialatela-Scafati O; Carucci M; Pancotti A; Galli C; Read M; Giurisato E; Romeo S; Russo I
PLoS One; 2015; 10(11):e0142509. PubMed ID: 26566224
[TBL] [Abstract][Full Text] [Related]
3. Dietary flavonoids fisetin and myricetin: dual inhibitors of Plasmodium falciparum falcipain-2 and plasmepsin II.
Jin H; Xu Z; Cui K; Zhang T; Lu W; Huang J
Fitoterapia; 2014 Apr; 94():55-61. PubMed ID: 24468190
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target.
Nezami A; Luque I; Kimura T; Kiso Y; Freire E
Biochemistry; 2002 Feb; 41(7):2273-80. PubMed ID: 11841219
[TBL] [Abstract][Full Text] [Related]
5. Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D.
Dali B; Keita M; Megnassan E; Frecer V; Miertus S
Chem Biol Drug Des; 2012 Apr; 79(4):411-30. PubMed ID: 22129033
[TBL] [Abstract][Full Text] [Related]
6. Antimalarial activity of HIV-1 protease inhibitor in chromone series.
Lerdsirisuk P; Maicheen C; Ungwitayatorn J
Bioorg Chem; 2014 Dec; 57():142-147. PubMed ID: 25462990
[TBL] [Abstract][Full Text] [Related]
7. New benzimidazole derivatives as antiplasmodial agents and plasmepsin inhibitors: synthesis and analysis of structure-activity relationships.
Saify ZS; Azim MK; Ahmad W; Nisa M; Goldberg DE; Hussain SA; Akhtar S; Akram A; Arayne A; Oksman A; Khan IA
Bioorg Med Chem Lett; 2012 Jan; 22(2):1282-6. PubMed ID: 22204908
[TBL] [Abstract][Full Text] [Related]
8. Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum.
Silva AM; Lee AY; Gulnik SV; Maier P; Collins J; Bhat TN; Collins PJ; Cachau RE; Luker KE; Gluzman IY; Francis SE; Oksman A; Goldberg DE; Erickson JW
Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10034-9. PubMed ID: 8816746
[TBL] [Abstract][Full Text] [Related]
9. Expression and characterisation of plasmepsin I from Plasmodium falciparum.
Moon RP; Tyas L; Certa U; Rupp K; Bur D; Jacquet C; Matile H; Loetscher H; Grueninger-Leitch F; Kay J; Dunn BM; Berry C; Ridley RG
Eur J Biochem; 1997 Mar; 244(2):552-60. PubMed ID: 9119023
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based inhibitors of the aspartyl protease plasmepsin II as potential antimalarial agents.
Gupta D; Yedidi RS; Varghese S; Kovari LC; Woster PM
J Med Chem; 2010 May; 53(10):4234-47. PubMed ID: 20438064
[TBL] [Abstract][Full Text] [Related]
11. Downstream effects of haemoglobinase inhibition in Plasmodium falciparum-infected erythrocytes.
Naughton JA; Nasizadeh S; Bell A
Mol Biochem Parasitol; 2010 Oct; 173(2):81-7. PubMed ID: 20478341
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, antimalarial evaluation and molecular modeling studies of hydroxyethylpiperazines, potential aspartyl protease inhibitors, part 2.
Cunico W; Gomes CR; Facchinetti V; Moreth M; Penido C; Henriques MG; Varotti FP; Krettli LG; Krettli AU; da Silva FS; Caffarena ER; de Magalhães CS
Eur J Med Chem; 2009 Sep; 44(9):3816-20. PubMed ID: 19403210
[TBL] [Abstract][Full Text] [Related]
13. Click Inspired Synthesis of Novel Cinchonidine Glycoconjugates as Promising Plasmepsin Inhibitors.
Mishra N; Agrahari AK; Bose P; Singh SK; Singh AS; Tiwari VK
Sci Rep; 2020 Feb; 10(1):3586. PubMed ID: 32108142
[TBL] [Abstract][Full Text] [Related]
14. QSAR, docking and ADMET studies of artemisinin derivatives for antimalarial activity targeting plasmepsin II, a hemoglobin-degrading enzyme from P. falciparum.
Qidwai T; Yadav DK; Khan F; Dhawan S; Bhakuni RS
Curr Pharm Des; 2012; 18(37):6133-54. PubMed ID: 22670592
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Plasmodium falciparum plasmepsin V by ligand-based virtual screening.
Meissner KA; Kronenberger T; Maltarollo VG; Trossini GHG; Wrenger C
Chem Biol Drug Des; 2019 Mar; 93(3):300-312. PubMed ID: 30320974
[TBL] [Abstract][Full Text] [Related]
16. [Selective inhibitors of plasmepsin II from Plasmodium falciparum based on pepstatin].
Rumsh LD; Mikhaĭlova AG; Mikhura IV; Prudchenko IA; Chikin LD; Mikhaleva II; Kaliberda EN; Dergousova NI; Mel'nikov EE; Formanovskiĭ AA
Bioorg Khim; 2008; 34(6):739-46. PubMed ID: 19088746
[TBL] [Abstract][Full Text] [Related]
17. Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors.
Moura PA; Dame JB; Fidock DA
Antimicrob Agents Chemother; 2009 Dec; 53(12):4968-78. PubMed ID: 19752273
[TBL] [Abstract][Full Text] [Related]
18. Identification of acridinyl hydrazides as potent aspartic protease inhibitors.
Azim MK; Ahmed W; Khan IA; Rao NA; Khan KM
Bioorg Med Chem Lett; 2008 May; 18(9):3011-5. PubMed ID: 18417344
[TBL] [Abstract][Full Text] [Related]
19. Hemoglobin Degrading Proteases of Plasmodium falciparum as Antimalarial Drug Targets.
Qidwai T
Curr Drug Targets; 2015; 16(10):1133-41. PubMed ID: 25738296
[TBL] [Abstract][Full Text] [Related]
20. Exploring the flap pocket of the antimalarial target plasmepsin II: the "55 % rule" applied to enzymes.
Zürcher M; Gottschalk T; Meyer S; Bur D; Diederich F
ChemMedChem; 2008 Feb; 3(2):237-40. PubMed ID: 17918177
[No Abstract] [Full Text] [Related]
[Next] [New Search]
